IMNN-001 Clinical Trials (2026): 4 Studies for Fallopian Tube Cancer & Epithelial Ovarian Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 IMNN-001 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Fallopian Tube Cancer & Epithelial Ovarian Cancer) and 678 total planned enrollment. 1 Phase 3 IMNN-001 trial are listed. 2 IMNN-001 clinical trials are actively recruiting at 9 U.S. sites across 9 states. Most recent activity: NCT06915025 (Oct 2032).
Where to Participate: All IMNN-001 Trial Sites in the U.S. (9 sites across 9 states)
Every actively recruiting IMNN-001trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Advent Health | Orlando32804 | NCT06915025 | Map |
| MO | Washington University School of Medicine in St. Louis | St Louis63110 | NCT06915025 | Map |
| OK | OU Health, Stephenson Cancer Center | Oklahoma City73104 | NCT05739981 | Map |
| OR | Providence Cancer Institute | Portland97213 | NCT06915025 | Map |
| SD | Sanford Health | Sioux Falls57104 | NCT06915025 | Map |
| TN | Erlanger Health | Chattanooga37403 | NCT06915025 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT05739981 | Map |
| WA | Providence Sacred Heart Medical Center & Children's Hospital | Spokane99204 | NCT06915025 | Map |
| WI | Froedtert and The Medical College of Wisconsin | Milwaukee53226 | NCT06915025 | Map |
IMNN-001 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P1/P2 | 1 | 1 | 2 | |
| P3 | 1 | 1 |
Recruiting IMNN-001 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06915025 | OVATION-3Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | P3 | Epithelial Ovarian Cancer | 500 | Jul 2025 |
| NCT05739981 | MRDPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | P1/P2 | Ovarian Cancer | 30 | Feb 2023 |
IMNN-001 clinical trials by indication
Epithelial Ovarian Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06915025 | OVATION-3 | P3 | recruiting | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
| NCT03393884 | OVATION 2 | P1/P2 | active not recruiting | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) |
| NCT02480374 | — | P1 | completed | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer |
Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05739981 | MRD | P1/P2 | recruiting | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
IMNN-001 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| OVATION-3 | NCT06915025 | P3 | recruiting | Epithelial Ovarian Cancer | 500 | — |
All IMNN-001 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06915025 | OVATION-3 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | P3 | recruiting | 500 | Imunon | Jul 2025 |
| NCT05739981 | MRD | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | P1/P2 | recruiting | 30 | Imunon | Feb 2023 |
| NCT03393884 | OVATION 2 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) | P1/P2 | active not recruiting | 130 | Imunon | Sep 2018 |
| NCT02480374 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | P1 | completed | 18 | Imunon | Sep 2015 |
IMNN-001 clinical trials: frequently asked questions
- How many IMNN-001 clinical trials are there?
- 4 IMNN-001 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 1 is marked completed.
- Are IMNN-001 clinical trials recruiting in 2026?
- Yes — 2 IMNN-001 trials are actively recruiting in 2026, with 9 U.S. sites across 9 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is IMNN-001 being studied for?
- IMNN-001 is being studied for Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma. The trials are grouped by indication on this page.
- What phase is IMNN-001 in?
- IMNN-001 clinical trials span 1 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors IMNN-001 clinical trials?
- The lead sponsor across the most IMNN-001 trials is Imunon. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming IMNN-001as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: